2026年11月12日,据欧盟食品安全局(EFSA)消息,欧盟营养、新型食品和食物过敏原(NDA)研究小组就山竹果皮提取物(Garcinia mangostana L. peel extract)作为新型食品的安全性发表科学意见。
经过评估,专家小组得出结论,根据现有数据,无法确定山竹果皮提取物作为新型食品的安全性。部分原文报道如下:
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on Garcinia mangostana L. (mangosteen) peel extract as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a dried, hydro-alcoholic extract obtained from the peel (pericarp and skin) of the fruit of the mangosteen tree, G. mangostana L. The applicant intends to market the NF for use in food supplements, at a maximum dose of 200 mg per day. The target population proposed by the applicant is the general adult population. The NF is intended to be marketed as standardised to 44%–52% total xanthones, which includes 26%–34% α-mangostin and 2%–6% γ-mangostin. The NF showed no genotoxic potential in the provided genotoxicity studies. However, marked cytotoxicity severely restricted the doses that could be tested. The Panel considers the available data insufficient to rule out genotoxicity concerns of the NF. In the provided subchronic toxicity study with the NF in rats, several findings of concern were noted. Marked increases in alanine aminotransferase and total bilirubin concentrations, indicative of liver toxicity, were already observed at the lowest dose. Increases in urea and blood urea nitrogen concentrations, starting at the mid-dose, point towards kidney toxicity. The lower body weight gains resulting in lower final body weights in all the groups that received the NF compared to the control groups suggests general toxicity of the NF. The Panel considers that a reference point cannot be derived from this study and that, based on the evidence provided, a safe dose for the NF cannot be established. The Panel concludes that the safety of the NF, G. mangostana L. (mangosteen) peel extract, cannot be established.









